The treatment of multiple myeloma (MM) has dramatically changed over the past year and the new standard of care in 2016 may not only lead to improved quality of life for patients but also improved overall survival (OS). In 2015, The U.S. Food and Drug Administration approved an unprecedented number of new agents for multiple myeloma, including daratumumab, elotuzumab, ixazomib, panobinostat, and carfilzomib.
Ravi Vij, MD, MBA, who is a professor of medicine in the Division of Medical Oncology at Washington University School of Medicine, St. Louis, MO, said the approval of these agents marks a dramatic change in the management of patients with MM and is a significant milestone. “With approval of these new drugs over the last 12 months we have more options for the treatment of patients with MM. In the future, these drugs will be explored in novel combination regimens and several may move into earlier lines of therapy which will likely add further to improvements in outcomes for patients with myeloma,” said Dr Vij.